OncoQuest Pharmaceuticals Inc Total Liabilities
OncoQuest Pharmaceuticals Inc total liabilities. Based on the latest financial reports, OncoQuest Pharmaceuticals Inc (078590) has total liabilities worth ₩19.38 Billion KRW (≈ $13.13 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OncoQuest Pharmaceuticals Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of OncoQuest Pharmaceuticals Inc (2014–2025)
Total liabilities of OncoQuest Pharmaceuticals Inc from 2014 to 2025. This chart illustrates how OncoQuest Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore 078590 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
OncoQuest Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of OncoQuest Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cellectis SA
NASDAQ:CLLS
|
USA | $226.30 Million |
|
AMTD IDEA Group
NYSE:AMTD
|
USA | $385.38 Million |
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
USA | $28.02 Million |
|
Dimerix Ltd
AU:DXB
|
Australia | AU$77.80 Million |
|
AnaPass Inc
KQ:123860
|
Korea | ₩65.15 Billion |
|
Neuraxis, Inc.
NYSE MKT:NRXS
|
USA | $3.00 Million |
|
DT Cloud Star Acquisition Corporation Units
NASDAQ:DTSQU
|
USA | $1.62 Million |
|
TIAN GE INT.HLDGS DL-0001
F:04T
|
Germany | €355.78 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down OncoQuest Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of OncoQuest Pharmaceuticals Inc.
Liquidity & Leverage Metrics
OncoQuest Pharmaceuticals Inc Total Liabilities Ratios Explained
OncoQuest Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OncoQuest Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OncoQuest Pharmaceuticals Inc (2014–2025)
The table below shows the annual total liabilities of OncoQuest Pharmaceuticals Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩32.66 Billion ≈ $22.14 Million |
+19.23% |
| 2024-12-31 | ₩27.40 Billion ≈ $18.57 Million |
+154.34% |
| 2023-12-31 | ₩10.77 Billion ≈ $7.30 Million |
+15.50% |
| 2022-12-31 | ₩9.33 Billion ≈ $6.32 Million |
-80.24% |
| 2019-12-31 | ₩47.21 Billion ≈ $31.99 Million |
+7.42% |
| 2018-12-31 | ₩43.95 Billion ≈ $29.78 Million |
+330.22% |
| 2017-12-31 | ₩10.21 Billion ≈ $6.92 Million |
+40.75% |
| 2016-12-31 | ₩7.26 Billion ≈ $4.92 Million |
+5.27% |
| 2015-12-31 | ₩6.89 Billion ≈ $4.67 Million |
-28.24% |
| 2014-12-31 | ₩9.61 Billion ≈ $6.51 Million |
-- |
About OncoQuest Pharmaceuticals Inc
DIAC Co., Ltd. engages in the car interior and exterior materials business in South Korea and internationally. DIAC Co., Ltd. was founded in 1993 and is headquartered in Miryang-si, South Korea.